Affymax, Inc. CEO Arlene Morris Joins Nuon Therapeutics Inc.'s Board of Directors as Chair

SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, announced today that Arlene Morris, president and CEO of Affymax, Inc. (Nasdaq:AFFY), has been elected chairperson of the company’s Board of Directors. A proven commercial leader in the biotechnology and pharmaceutical industry with more than 25 years of experience, Ms. Morris is well suited to work with the management team at Nuon Therapeutics.